| Abstract: | In order to determine the safety of Bacillus amyloliquefaciens SSY1, we carried out the acute toxicity, chronic toxicity, bacterial translocation, product of metabolism and drug susceptibility test. Acute toxicity test in high dose groups (1.30×1010 CFU/mL), middle dose group(0.90×1010 CFU/mL), low dose group (0.65×1010 CFU/mL) and normal saline control group. After the acute toxicity test, the mice were sacrificed 14 days after the observation. Chronic toxicity test of each group was administered once a day for 30 d, chronic toxicity test in high dose groups (0.65×1010 CFU/mL), middle dose group (0.65×109 CFU/mL), low dose group (0.65×108 CFU/mL) and normal saline control group. The results showed that all mice were without exception phenomenon, the spirit, appetite, behavior and feces and so on, no pathological changes were found on the acute toxicity test. Chronic toxicity test of the mice were no abnormal clinical changes, and there were no pathological changes. Body weight and feed utilization rate of mice, hematology, blood biochemistry indexes and viscera coefficient difference were not significant (P>0.05);Bacillus amyloliquefaciens SSY1 strain did not occur translocation in mice, amino acid decarboxylase and indole test were negative, among the 24 kinds of commonly used drugs, the strains were sensitive to 23 kinds of drugs except the cillimycin. This experiment proved that Bacillus amyloliquefaciens SSY1 had good security. |
